Phaseline

Companies › Black Diamond Therapeutics

Black Diamond Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
silevertinib (BDTX-1535)
4th generation irreversible EGFR inhibitor targeting classical and non-classical driver an
EGFRPhase 2Glioblastoma (GBM); Non-Small Cell Lung CancerDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05256290silevertinib (BDTX-1535)Phase 1Non-Small Cell Lung CancerOncologyDec 2027
NCT07326566silevertinib (BDTX-1535)Phase 2Glioblastoma (GBM)OncologyNov 2028

From the company's SEC filings

Cash and short-term investments of $102m on 2026-09-30; operating cash outflow about $36m a year; runway about 34 months at that burn, to Aug 2029; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

EGFR (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group

Companies built like this

Wayshine Biopharm ArriVent BioPharma Teligene US Nanjing Sanhome Pharmaceutical Jiangsu Aosaikang Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.